Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck
Woman and Man
Between 18 years
and 99 years
Merck KGaA
Update Il y a 4 ans
Étude EMR 100070-005 : étude de phase 3 comparant l’avélumab avec un doublet à base de platine comme traitement de première ligne chez des patients ayant un cancer de poumon non à petites cellules récurrent ou de stade IV et positif pour PD-L1. [essai clos aux inclusions]
Le cancer de poumon non à petites cellules est le type de cancer de poumon le plus fréquent, qui représente 85-90% de l’ensemble des cancers de poumon. Les traitements principaux du cancer du poumon n...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension
To study the effects of losartan compared to placebo (nonhypertensives) or amlodipine (hypertensives) on reduction of proteinuria in children and adolescents up to 17 years of age with hypertension (i...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
A Randomized Clinical Trial to Evaluate the Effects of High Dose Statin and Niacin Therapy on Excised Plaque Biomarkers in Patients Undergoing Carotid Endarterectomy (CEA)
To determine whether 4 to 12 weeks of treatment with atorvastatin 80 mg/day + niacin ER 2 g/day compared to low dose atorvastatin 10 mg/day will result in a difference in the following endpoints: (1...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Serono SA - Geneva
Update Il y a 4 ans
A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson?s disease treated with a stable dose of a single dopamine agonist
The primary objective is to evaluate the time to first intervention of two doses of safinamide (50 and 100 mg/day) compared to placebo as add-on therapy to a single dopamine agonist.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Dialysis and Who Have Inadequate Glycemic Control
After 54 weeks, to assess the effect (change from baseline) of sitagliptin on HbA1c; After 54 weeks, to assess the safety and tolerability of sitagliptin.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A study to evaluate the safety and efficacy of the addition of a new drug (MK-3102) in patients with Type 2 Diabetes who are also receiving Glimepiride and Metformin
(1) After 24 weeks, to assess the effect of the addition of treatment with MK- 3102 compared with the addition of placebo on A1C. (2) To assess the safety and tolerability of MK 3102.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp
Update Il y a 4 ans
Clinical Trial testing the combination of MK-5172 and MK-8742 with Ribavirin in people with Hepatitis C Ensayo clínico para evaluar la combinación de MK 5172 y MK 8742 con ribavirina (RBV) en sujetos con hepatitis C
In treatment naïve (TN) non-cirrhotic subjects with chronic HCV infection with GT2, 4, 5 or 6: (1)Objective: To evaluate the efficacy of MK-5172 in combination with or without MK-8742 and/or RBV for ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Immunotherapeutic treatment with Pembrolizumab (antibody) in patients with early stage non-small cell lung cancer Tratamiento inmunoterápico con Pembrolizumab (anticuerpo) en pacientes en estadios iniciales de cáncer pulmonar no microcítico
To prospectively investigate whether adjuvant treatment with pembrolizumab after completion of radical surgery (lobectomy/pneumonectomy) with or without standard adjuvant chemotherapy for stage IB (T ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck B.V. (The Netherlands)
Update Il y a 4 ans
Ovulation induction in women with newly diagnosed polycystic ovary syndrome: a randomised double blind clinical trial comparing clomiphene citrate plus metformin with clomiphene citrate plus placebo
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 65 years and 85 years
Merckle GmbH
Update Il y a 4 ans
AVOID : Essai de phase 3 randomisé, comparant l’efficacité et la tolérance du lipegfilgrastim à celle du pegfilgrastim, chez des patients âgés ayant un lymphome non-hodgkinien agressif à cellules B à haut risque de neutropénie et traité par une chimiothérapie de type R-CHOP-21. [essai clos aux inclusions]
L’objectif de cet essai est de comparer l’efficacité et la tolérance du lipegfilgrastim et du pegfilgrastim, chez des patients âgés ayant un lymphome non-hodgkinien agressif à cellules B et à haut ris...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Chimiothérapie
,
Gériatrie
Essai clos aux inclusions
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next